In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis.
Two oxazolidinones (U100592 and U100766), trovafloxacin, and a streptogramin combination (dalfopristin-quinupristin) were highly active in vitro against Staphylococcus aureus and Staphylococcus epidermidis, including methicillin-resistant strains. Trovafloxacin was more active than ciprofloxacin. Time-kill synergy studies demonstrated indifference for the oxazolidinones combined with vancomycin and rifampin against methicillin-resistant staphylococci. Spontaneous resistance was observed with all agents.
Mulazimoglu
L
L
Section of Infectious Diseases, Marmara University School of Medicine, Istanbul, Turkey.
Drenning
S D
SD
Yu
V L
VL
D000081:Acetamides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D024841:Fluoroquinolones; D006801:Humans; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000494:pharmacology*; D010080:Oxazoles / Q000494:pharmacology*; D023303:Oxazolidinones; D013203:Staphylococcal Infections / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*; D013212:Staphylococcus epidermidis / Q000187:drug effects*; D013997:Time Factors; D014769:Virginiamycin / Q000494:pharmacology*
D000081:Acetamides; D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D010080:Oxazoles; D023303:Oxazolidinones; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; C080163:trovafloxacin; C098011:eperezolid; D000069349:Linezolid